Mass Spectral Fingerprinting in Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

393 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-05-31

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To answer the question whether a disease specific profile of breath in patients with lung cancer can be detected by an untargeted metabolomic study using exhaled breath analysis by mass spectrometry.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detecting Lung Cancer Based on Exhaled Breath

NCT04419207

Carcinoma Lung Cancer NSCLC +1 more

COMPLETED

Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung Cancer

NCT00002667

Lung Cancer

COMPLETED NA

Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening.

NCT06016569

Lung Cancer

RECRUITING NA

Canine-Assisted Profiling of Lung Cancer From Human Breath

NCT02759679

Lung Cancer

TERMINATED NA

Development and Application of Molecular Evaluation Instrument for Lung Cancer Diagnosis and Treatment

NCT06086587

Lung Cancer

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

100 patients with lung cancer

* Group A: 70 patients with any type of lung cancer eligible for lung cancer surgery
* Group B: 30 patients with any type of lung cancer not eligible to surgery (small-cell carcinoma, squamous cell carcinoma, adenocarcinoma, large-cell carcinoma).

No intervention

Intervention Type OTHER

60 controls

60 controls (group C) matched for age, gender, smoking history.

No intervention

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed lung cancer based on cytological or histological analysis.
* Group A: any type of lung cancer eligible for surgical resection (up to TNM stage IIIa).
* Group B: any type of lung cancer (small-cell carcinoma, non-small-cell carcinoma) not amenable for surgical resection.
* Group C: matched controls.
* Age between 18 and 85 years at study entry

Exclusion Criteria

* Another 'active' secondary malignant disease (e.g. breast cancer, colon carcinoma) in group A and B, presence of any active malignant disease in group C (based on personal information).
* Acute inflammatory disease (e.g. common cold) within the last 4 weeks.
* Any other acute lung disease which affects breath measurements
* Acute or chronic hepatic disease.
* Renal failure or renal replacement therapy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No